Ser329

Site Information
AtGEGGAsDLPEDPD SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 20622224

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 3 , 4 , 5 , 6 )
Disease tissue studied:	leukemia ( 5 ) , acute myelogenous leukemia ( 5 ) , lung cancer ( 4 ) , non-small cell lung cancer ( 4 )
Relevant cell line - cell type - tissue:	293E (epithelial) ( 6 ) , Calu 6 (pulmonary) ( 4 ) , H2009 (pulmonary) ( 4 ) , H2077 (pulmonary) ( 4 ) , H2887 (pulmonary) ( 4 ) , H322M (pulmonary) ( 4 ) , HCC1359 (pulmonary) ( 4 ) , HCC4006 (pulmonary) ( 4 ) , HCC827 (pulmonary) ( 4 ) , HeLa (cervical) ( 1 ) , K562 (erythroid) ( 3 ) , KG-1 (myeloid) ( 5 ) , LCLC-103H (pulmonary) ( 4 ) , NCI-H1648 (pulmonary) ( 4 )

References
1	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
2	Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21 23312004 Curated Info
3	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
4	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
5	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
6	Hsu PP, et al. (2011) The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 332, 1317-22 21659604 Curated Info